Abstract
Although previous studies have reported clinical improvement of hidradenitis suppurativa (HS) using intravenous (IV) ertapenem, the sustained efficacy of this broad-spectrum antibiotic has yet to be elucidated. We conducted an IRB-approved retrospective chart review of patients at the Montefiore/Einstein HS Treatment Center who completed 6 weeks of IV ertapenem. Disease severity (HS-Physician Global Assessment [HS-PGA]; Numerical Rating Scale [NRS] pain scores) was documented at pre-, during-, and post-treatment visits.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
